{
  "docId": "019de075-ab2a-73e5-980a-7d480707ba09",
  "docSlug": "340a1966b9939070959283ec1665bfbf",
  "documentTitle": "Kymera | Investor Presentation Deck | 60 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 60,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "traction",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 15,
  "notes": "HS = Hidradenitis Suppurativa, AD = Atopic Dermatitis, HV = Healthy Volunteers, PK = Pharmacokinetics, PD = Pharmacodynamics, MS = Mass Spectrometry, LLOQ = Lower Limit of Quantitation.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-ab2a-73e5-980a-7d480707ba09/16",
  "deckHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09",
  "deckJsonHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09.json",
  "deckAnchorHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.7,
        "y": 0.15
      },
      "kind": "chart",
      "text": "IRAK4 Levels in PBMC in Patients at Day 28 (MS)",
      "attrs": null,
      "subkind": "box",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ca15d45-b6df-4867-8ea2-a64e8358f755",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.3,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Part C KT-474 Plasma PK",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6180c61c-0722-4285-ac0b-731c0f5c703c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.38,
        "y": 0.15
      },
      "kind": "chart",
      "text": "PK/PD Correlation in Plasma/Monocytes (FLOW)",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b72c89b-2af6-4659-adc7-5ba41bf32ca3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "list",
      "text": "KT-474 PK at the 75 mg QD dose (fed state) in patients is comparable to 100 mg QD (fasted state) in HV. Mean Cmax and Ctrough levels at steady state in Part C are in line with MAD3 levels at Day 14. Mean half-life of 44 hours is within range.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2fe99332-f33d-4bd5-ba1d-a293f391278c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.38,
        "y": 0.65
      },
      "kind": "list",
      "text": "KT-474 concentrations in plasma lead to same level of IRAK4 degradation in HV (n=48) and HS/AD (n=20) patients. Concentrations above 3 ng/mL lead to same level of degradation (>80%) in HV and Patients.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a69fbd1-ed93-4476-a573-850835f912dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.7,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "HS and AD Patients IRAK4 Levels at Day 28 (n=4) near LLOQ",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a50a410a-3dea-4bbb-9ee5-39b2e47e91f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.02
      },
      "kind": "title",
      "text": "KT-474 Plasma PK and IRAK4 Degradation in HS and AD Patients Dosed for 28 Days is Comparable to HV",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "041d5094-1824-4dfc-bc30-dbbf483d147d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 9,
      "beatId": "285a4680-d771-4271-8dc2-ebdc0e60f9a4",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Desire",
      "beatSlug": "aida-desire",
      "evidence": "The slides on Kymera's pipeline and clinical data create desire for the solution",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}